华兰生物(002007.SZ)：重组Exendin-4-Fc融合蛋白注射液获准开展临试

Core Viewpoint - The company Hualan Biological (002007.SZ) has received approval from the National Medical Products Administration for a new drug clinical trial, expanding the indications for its drug HL08 to include weight control in obese patients in addition to its original indication for improving blood glucose control in type 2 diabetes patients [1] Group 1 - The drug HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The original indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - The newly approved indication aims to assist in weight control for obese patients [1]